Some examples include the mRNA coding for the Wilms’ tumor protein (WT1) in clinical trial for the treatment of acute and chronic myeloid leukemia, multiple myeloma, mesothelioma, and glioblastoma; the mRNA coding for CD40L in clinical trial for the treatment of renal and pancreatic cancer; and a brain tumor stem cells-specific mRNA for the treatment of glioblastoma. This evidence concerns the gene WT1 and chronic myelogenous leukemia, BCR-ABL1 positive.